Main Menu

The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities.

Novel CD8+ T cell receptors (TCRs) isolated from elite HIV controllers show unprecedented affinity for conserved HIV epitopes, offering new avenues for direct immunotherapies and T cell engineering. These TCRs exhibit potential for cytotoxicity mediation against HIV-infected cells, with prospects for use in toxin-coupled treatments or as part of engineered T cell therapies. Collaborations, such as with Altor Biosciences, are enhancing these TCRs with proprietary molecules like IL-15, to bolster therapeutic efficacy.

The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01—targeting the CD4 binding site—and PGT121—targeting the V3 glycan—has shown promising results.

The technology focuses on developing clonal lineage antibodies targeting the CD4 binding site of HIV-1, serving as templates for an effective HIV-1 vaccine. Developed through collaboration with Duke, Boston, and Stanford Universities, the patent filed by Duke University in 2012. These antibodies exhibit neutralizing activity against HIV-1, designed for therapeutic and prophylactic benefits, targeting a critical site of vulnerability on the virus to stimulate the immune system.

The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods.

The development of an infectious molecular clone of simian immunodeficiency virus SIVsm, known as SIVsmE543-3, marks a significant breakthrough in SIV research. This clone, derived from a late-stage biological isolate from an immunodeficient rhesus macaque with SIV-induced encephalitis, has shown robust replication in macaque immune cells and macrophages. Notably, SIVsmE543-3 exhibits resistance to neutralization by heterologous sera, which can typically neutralize genetically diverse SIV variants in vitro.

The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies.

This innovative technology represents a significant advancement in the field of HIV-1 therapy and prevention. By targeting a second, quaternary CD4-binding site with the engraftment of the VRC03 FR3 loop, it enhances the potency of broadly neutralizing antibodies against HIV-1. Importantly, this approach also addresses issues of autoreactivity and extends the antibody's half-life in vivo.

The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.

The development of 5C4, a monoclonal antibody targeting the prefusion conformation of the Respiratory Syncytial Virus (RSV) Fusion (F) glycoprotein, represents a significant advancement in RSV vaccine research. Unlike the postfusion state, the prefusion conformation of the F glycoprotein contains unique epitopes targeted by neutralizing antibodies.